M.D. Minden

405 total citations
16 papers, 289 citations indexed

About

M.D. Minden is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, M.D. Minden has authored 16 papers receiving a total of 289 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 7 papers in Molecular Biology and 5 papers in Public Health, Environmental and Occupational Health. Recurrent topics in M.D. Minden's work include Acute Myeloid Leukemia Research (8 papers), Acute Lymphoblastic Leukemia research (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). M.D. Minden is often cited by papers focused on Acute Myeloid Leukemia Research (8 papers), Acute Lymphoblastic Leukemia research (4 papers) and Chronic Myeloid Leukemia Treatments (3 papers). M.D. Minden collaborates with scholars based in Canada, United States and Netherlands. M.D. Minden's co-authors include E. A. McCulloch, Jim Dimitroulakos, Zhenlei Xia, W. Wei‐Lynn Wong, Linda Z. Penn, Guisheng Yang, Zhenbo Hu, Sergey Krysov, Katja Zirlik and Graham Packham and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Stem Cells.

In The Last Decade

M.D. Minden

15 papers receiving 278 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
M.D. Minden Canada	7	152	87	86	74	52	16	289
Kati Servan Germany	6	224 1.5×	105 1.2×	69 0.8×	12 0.2×	119 2.3×	6	389
O. I. Olopade United States	9	209 1.4×	136 1.6×	44 0.5×	22 0.3×	195 3.8×	14	491
Margit Stimpfl Austria	11	193 1.3×	68 0.8×	90 1.0×	20 0.3×	105 2.0×	16	372
Limengmeng Wang China	11	160 1.1×	38 0.4×	107 1.2×	19 0.3×	40 0.8×	31	320
Masafumi MURAI Japan	7	318 2.1×	106 1.2×	21 0.2×	40 0.5×	71 1.4×	19	430
Zhen Shang China	10	242 1.6×	91 1.0×	135 1.6×	19 0.3×	100 1.9×	35	390
Devorah Olam Israel	11	214 1.4×	94 1.1×	62 0.7×	46 0.6×	133 2.6×	15	453
Ekaterina A. Alekseeva Russia	8	108 0.7×	56 0.6×	33 0.4×	14 0.2×	64 1.2×	21	287
Günther Bode Germany	7	234 1.5×	76 0.9×	48 0.6×	60 0.8×	35 0.7×	7	359
Daniel Onofre Vidal Brazil	13	389 2.6×	226 2.6×	40 0.5×	87 1.2×	63 1.2×	31	530

Countries citing papers authored by M.D. Minden

Since Specialization

Citations

This map shows the geographic impact of M.D. Minden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M.D. Minden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M.D. Minden more than expected).

Fields of papers citing papers by M.D. Minden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by M.D. Minden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M.D. Minden. The network helps show where M.D. Minden may publish in the future.

Co-authorship network of co-authors of M.D. Minden

This figure shows the co-authorship network connecting the top 25 collaborators of M.D. Minden. A scholar is included among the top collaborators of M.D. Minden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with M.D. Minden. M.D. Minden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

Murphy, Tracy, Andrea Arruda, Sze Wah Samuel Chan, et al.. (2019). PS961 PATIENTS WITH RELAPSED MIXED PHENOTYPE ACUTE LEUKEMIA HAVE SHORT REMISSION DURATION WITH RE‐INDUCTION: A SINGLE CENTER EXPERIENCE. HemaSphere. 3(S1). 432–433. 1 indexed citations

Seymour, J.F., Rena Buckstein, Valeria Santini, et al.. (2017). Azacitidine Versus Conventional Care Regimens (CCR) in Elderly Patients (≥75 Years) with Acute Myeloid Leukemia (AML) in the AZA-AML-001 Study. Leukemia Research. 55. S67–S68. 1 indexed citations

Tang, Lanlan, Anna Dolnik, Kyle J. MacBeth, et al.. (2017). Impact of Gene Mutations on Survival with Azacitidine or Conventional Care Regimens (CCR) in Older Patients with Acute Myeloid Leukemia. Leukemia Research. 55. S69–S70. 1 indexed citations

Minden, M.D., Cornelis A.M. van Bergen, Sergey Krysov, et al.. (2015). Lectins from opportunistic bacteria interact with acquired variable-region glycans of surface immunoglobulin in follicular lymphoma. Blood. 125(21). 3287–3296. 53 indexed citations

Culos‐Reed, S. Nicole, et al.. (2010). A pilot study of a home-based exercise intervention for adult patients with AML.. Journal of Clinical Oncology. 28(15_suppl). e19570–e19570. 1 indexed citations

Kornblau, Steven M., M.D. Minden, David B. Rosen, et al.. (2009). Single Cell Network Profiles in Non-M3 AML Associated with Patient Response to Standard Induction Therapy.. Blood. 114(22). 1582–1582. 1 indexed citations

Crump, Michael, Brian Leber, Jeannine Kassis, et al.. (2004). A randomized phase I clinical and biologic study of two schedules of BAY 43–9006 in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML): A National Cancer Institute of Cancer Clinical Trials Group Study. Journal of Clinical Oncology. 22(14_suppl). 6611–6611. 2 indexed citations

Gupta, Vikas, Suzanne Kamel‐Reid, M.D. Minden, et al.. (2003). Imatinib Mesylate (Gleevec™) is a Useful Agent in the Salvage Treatment of Adults with Relapsed/refractory Philadelphia Positive Acute Leukemias. Hematology. 8(3). 139–143. 6 indexed citations

Wong, W. Wei‐Lynn, et al.. (2001). Cerivastatin triggers tumor-specific apoptosis with higher efficacy than lovastatin. PubMed. 7(7). 2067–75. 113 indexed citations

10.

Hu, Zhenbo, M.D. Minden, & E. A. McCulloch. (1996). Regulation of the synthesis of bcl-2 protein by growth factors.. PubMed. 10(12). 1925–9. 16 indexed citations

11.

Hu, Zhenbo, et al.. (1995). Mechanism of cytosine arabinoside toxicity to the blast cells of acute myeloblastic leukemia: involvement of free radicals.. PubMed. 9(5). 789–98. 47 indexed citations

12.

Yang, Guisheng, M.D. Minden, & E. A. McCulloch. (1994). Regulation by retinoic acid and hydrocortisone of the anthracycline sensitivity of blast cells of acute myeloblastic leukemia.. PubMed. 8(12). 2065–75. 27 indexed citations

13.

Curtis, J. E., H. A. Messner, M.D. Minden, et al.. (1992). High-dose cytosine arabinoside remission induction for acute myelogenous leukemia: comparison of two regimens of remission maintenance.. PubMed. 6(11). 1192–8. 6 indexed citations

14.

McCulloch, E. A., M.D. Minden, & J. E. Curtis. (1990). The influence of growth regulation on treatment strategy for acute myeloblastic leukaemia.. PubMed. 9(1). 169–98. 7 indexed citations

15.

McCulloch, E. A., et al.. (1987). Genetically Determined Regulators Acting on the Blast Cells of Acute Myeloblastic Leukemia. Acta Haematologica. 78(1). 18–25. 2 indexed citations

16.

Minden, M.D., J. Curtis, & H. A. Messner. (1986). Origin of leukemic relapse after bone marrow transplantation detected by restriction fragment-length polymorphism. Stem Cells. 4(S1). 194–196. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact